AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31306183 — intervention group
Group type: COMPARATOR
Intervention: Control (DSM-5 reference standard)
Number of subjects: 176
Study 31306318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 1295
Study 31306318 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 1295
Study 31306555 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg once daily for 4 weeks, with dose adjustments thereafter
Number of subjects: 28
Study 31306621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior acute coronary syndromes
Number of subjects: 39679
Study 31306621 — intervention group
Group type: COMPARATOR
Intervention: OAC ± AP therapy
Number of subjects: 39679
Study 31306621 — intervention group
Group type: EXPERIMENTAL
Intervention: AP therapy
Number of subjects: 39679
Study 31306621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual AP therapy
Number of subjects: 39679
Study 31306621 — intervention group
Group type: COMPARATOR
Intervention: OAC with or without AP therapy
Number of subjects: 39679
Study 31307216 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal DENV neutralizing antibodies
Number of subjects: 139
Study 31307216 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV-4 neutralizing antibody
Number of subjects: 139
Study 31307393 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment
Number of subjects: 0
Study 31307393 — intervention group
Group type: COMPARATOR
Intervention: Cox Proportional Hazard (Cox-PH) model
Number of subjects: 0
Study 31307393 — intervention group
Group type: COMPARATOR
Intervention: Generalized Additive Model (GAM)
Number of subjects: 0
Study 31307393 — intervention group
Group type: COMPARATOR
Intervention: Cox-SPDE model
Number of subjects: 0
Study 31307393 — intervention group
Group type: EXPERIMENTAL
Intervention: SPDE models
Number of subjects: 0
Study 31307443 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the Nursing Home Survey on Patient Safety Culture (NHSOPS) questionnaire
Number of subjects: 61
Study 31307443 — intervention group
Group type: EXPERIMENTAL
Intervention: French version of the NHSOPS questionnaire
Number of subjects: 61
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (<50 nmol/L)
Number of subjects: 500
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (50-75 nmol/L)
Number of subjects: 500
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D replete (>75 nmol/L)
Number of subjects: 500
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D deficient
Number of subjects: 500
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D insufficient
Number of subjects: 500
Study 31307482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted live birth rates for vitamin D replete
Number of subjects: 500
Study 31307502 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedition: Strategic Advantage (active program)
Number of subjects: 100
Study 31307502 — intervention group
Group type: COMPARATOR
Intervention: Expedition: Informational Advantage (control program)
Number of subjects: 100
Study 31307542 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnostic criteria (Amsterdam II criteria and revised Bethesda guidelines)
Number of subjects: 111
Study 31307542 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC of MMR proteins
Number of subjects: 111
Study 31307542 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI test
Number of subjects: 111
Study 31307542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IHC and MSI test
Number of subjects: 111
Study 31307859 — intervention group
Group type: EXPERIMENTAL
Intervention: PMD
Number of subjects: 0
Study 31307859 — intervention group
Group type: EXPERIMENTAL
Intervention: SCZ
Number of subjects: 0
Study 31307859 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 0
Study 31307859 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 0
Study 31308059 — intervention group
Group type: EXPERIMENTAL
Intervention: CDX-3379 (1,000 mg) administered as two infusions at a 2-week interval
Number of subjects: 12
Study 31308835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (6-day once-daily administration)
Number of subjects: 0
Study 31308835 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (10-day twice-daily administration)
Number of subjects: 0
Study 31308835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Number of subjects: 0
Study 31308835 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study 31308926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HFpEF and T2D
Number of subjects: 140
Study 31308926 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 140
Study 31309541 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CHOP-like chemotherapy
Number of subjects: 0
Study 31309911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponderal index at birth in infertile women
Number of subjects: 125
Study 31309911 — intervention group
Group type: COMPARATOR
Intervention: Ponderal index at birth in fertile women
Number of subjects: 125
Study 31310310 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) therapy for 8 years
Number of subjects: 24
Study 31310353 — intervention group
Group type: EXPERIMENTAL
Intervention: Development and implementation of a transmural care pathway for self-management support.
Number of subjects: 0
Study 31310994 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 930
Study 31310994 — intervention group
Group type: COMPARATOR
Intervention: Teens with obesity
Number of subjects: 930
Study 31310994 — intervention group
Group type: COMPARATOR
Intervention: Boys
Number of subjects: 930
Study 31310994 — intervention group
Group type: COMPARATOR
Intervention: Sundays
Number of subjects: 930
Study 31310994 — intervention group
Group type: COMPARATOR
Intervention: Weekend sedentary time
Number of subjects: 930
Study 31311438 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo Syndrome patients with malignancy
Number of subjects: 1604
Study 31311438 — intervention group
Group type: COMPARATOR
Intervention: Takotsubo Syndrome patients without malignancy
Number of subjects: 1604
Study 31311545 — intervention group
Group type: EXPERIMENTAL
Intervention: PCO-VP
Number of subjects: 126
Study 31311763 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223, 55 kBq/kg, every 4 weeks for ≤6 cycles
Number of subjects: 696
Study 31311898 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as the use of 5 or more medications at one time)
Number of subjects: 5000
Study 31311898 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-drug interactions (DDIs) determined using the Lexicomp Online drug interaction screening tool
Number of subjects: 5000
Study 31311898 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications defined based on the 2015 update of the Beers Criteria
Number of subjects: 5000
Study 31311898 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of comorbid disease recorded and scored according to Charlson Comorbidity Index (CCI)
Number of subjects: 5000
Study 31312030 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib and capecitabine (DL3 dose level)
Number of subjects: 34
Study 31312030 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib and capecitabine (DL3 dose level) in patients with RAS/RAF/MEK/ERK pathway mutations
Number of subjects: 34
Study 31312170 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31312536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (NIVO + IPI)
Number of subjects: 0
Study 31312536 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy (NIVO)
Number of subjects: 0
Study 31312536 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab monotherapy (IPI)
Number of subjects: 0
Study 31312806 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations (8-week interval)
Number of subjects: 24
Study 31312806 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations (24-week interval)
Number of subjects: 24
Study 31312806 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdV63.MVA/HIVconsv vaccination
Number of subjects: 24
Study 31313237 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 23
Study 31314614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified; details not available
Number of subjects: 0
Study 31314614 — intervention group
Group type: COMPARATOR
Intervention: Control not specified; details not available
Number of subjects: 0
Study 31314668 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcallosal cingulate cortex deep brain stimulation (SCC-DBS)
Number of subjects: 0
Study 31314757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin-naive PWE in Logo health zone
Number of subjects: 501
Study 31314757 — intervention group
Group type: EXPERIMENTAL
Intervention: Onchocerciasis-infected PWE in Aketi health zone
Number of subjects: 501
Study 31314757 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin snip-positive PWE
Number of subjects: 501
Study 31314907 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted interventions
Number of subjects: 51
Study 31314907 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 51
Study 31315600 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Check program
Number of subjects: 0
Study 31315600 — intervention group
Group type: COMPARATOR
Intervention: Current models of newborn screening
Number of subjects: 0
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive dataset of biomarkers measured longitudinally
Number of subjects: 650
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment including motor and neuro-psychological tests
Number of subjects: 650
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of biospecimens (stool, whole blood, cerebrospinal fluid)
Number of subjects: 650
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (structural and functional)
Number of subjects: 650
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG recordings (12-lead and Holter)
Number of subjects: 650
Study 31315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological and environmental data collection via Verily Study Watch
Number of subjects: 650
Study 31315794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 336
Study 31315858 — intervention group
Group type: EXPERIMENTAL
Intervention: Play.Care algorithm using data from iPad games
Number of subjects: 760
Study 31315863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethiopian Healthy Eating Index (EHEI) based on Food-Based Dietary Guidelines (FBDGs) using National Food Consumption Survey (NFCS) data.
Number of subjects: 0
Study 31315863 — intervention group
Group type: EXPERIMENTAL
Intervention: EHEI Score based on 24 hours diet recall.
Number of subjects: 0
Study 31315863 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Quality Screening tool scoring for important EHEI components.
Number of subjects: 0
Study 31315881 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCP team intervention in the ED
Number of subjects: 0
Study 31315881 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31315916 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with Down syndrome (DS)
Number of subjects: 100
Study 31315916 — intervention group
Group type: COMPARATOR
Intervention: Typically developing youth (control)
Number of subjects: 100
Study 31316378 — intervention group
Group type: EXPERIMENTAL
Intervention: Four off-label metabolically targeted medicines
Number of subjects: 0
Study 31316451 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based High-Intensity Interval Training
Number of subjects: 0
Study 31316452 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective pre-injury symptom ratings
Number of subjects: 0
Study 31316785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fecal microbiota transplant (FMT)
Number of subjects: 10
Study 31316786 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for diverticular disease
Number of subjects: 1206
Study 31316836 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study 31316984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating device (19 min plantar vibrating sequence)
Number of subjects: 29
Study 31317047 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-associated autologous chondrocyte implantation (ACI)
Number of subjects: 102
Study 31317047 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 102
Study 31317619 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescription at discharge
Number of subjects: 524
Study 31317619 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use during the 2 weeks after ED visit
Number of subjects: 524
Study 31317619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall opioid use at 3-month follow-up
Number of subjects: 524
Study 31318125 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during pregnancy (23 patients, 59%)
Number of subjects: 39
Study 31318125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (20 patients, 51%)
Number of subjects: 39
Study 31318125 — intervention group
Group type: EXPERIMENTAL
Intervention: Live births (31 live births reported)
Number of subjects: 39
Study 31318125 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (3 patients)
Number of subjects: 39
Study 31318125 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive staging (13 patients)
Number of subjects: 39
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: ECE staff comfort level in discussing healthy sleep with parents
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of sleep education into ECE
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder relevance rating of healthy sleep
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder priority rating of healthy sleep
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about links to health and development
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for linking sleep health to other issues
Number of subjects: 46
Study 31318273 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for awareness campaign
Number of subjects: 46
Study 31318840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) analysis of solithromycin
Number of subjects: 95
Study 31318840 — intervention group
Group type: COMPARATOR
Intervention: Liquid Plasma Samples (LPS) analysis of solithromycin
Number of subjects: 95
Study 31318902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie formula diet for six weeks followed by nine weeks of food reintroduction and stabilization
Number of subjects: 12
Study 31318902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie formula diet for six weeks
Number of subjects: 12
Study 31318954 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead level quartile
Number of subjects: 204
Study 31318954 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 204
Study 31319038 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 171
Study 31319038 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS + ATP stimulation
Number of subjects: 171
Study 31319038 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS + ATP + P2X7 selective inhibitor
Number of subjects: 171
Study 31319038 — intervention group
Group type: COMPARATOR
Intervention: P2RX7 diplotypes
Number of subjects: 171
Study 31319153 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-identical sibling donors (MSDs)
Number of subjects: 348
Study 31319153 — intervention group
Group type: COMPARATOR
Intervention: Matched donors (MDs)
Number of subjects: 348
Study 31319153 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell graft recipients
Number of subjects: 348
Study 31319153 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I-II aGVHD
Number of subjects: 348
Study 31319153 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III-IV aGVHD
Number of subjects: 348
Study 31319153 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive cGVHD
Number of subjects: 348
Study 31319498 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 31319498 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31319809 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional autonomy level change as assessed by the instrumental abilities of daily living (IADL) score
Number of subjects: 6780
Study 31319809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance and behavioral disorders changes over time
Number of subjects: 6780
Study 31319833 — intervention group
Group type: EXPERIMENTAL
Intervention: f-IPF
Number of subjects: 79
Study 31319851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dose PEF measured at home
Number of subjects: 8
Study 31319851 — intervention group
Group type: COMPARATOR
Intervention: Forced expiratory volume in one second (FEV)
Number of subjects: 8
Study 31319977 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and nab-paclitaxel
Number of subjects: 63
Study 31319994 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg once daily) plus Ruxolitinib (25 mg twice daily)
Number of subjects: 30
Study 31320006 — intervention group
Group type: EXPERIMENTAL
Intervention: vHPSD catheter ablation
Number of subjects: 52
Study 31320010 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic trajectory analysis of ranked signals (STAR) mapping method
Number of subjects: 35
Study 31320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated regional STEMI care networks
Number of subjects: 0
Study 31320346 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI hospitals
Number of subjects: 0
Study 31320346 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI hospital-based regional STEMI care network
Number of subjects: 0
Study 31320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-city STEMI care network
Number of subjects: 0
Study 31320352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 21 days for 6 weeks after the final dose of BCG)
Number of subjects: 15
Study 31320352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and intravesicular BCG therapy
Number of subjects: 15
Study 31320356 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG/ERP data recorded for 24 consecutive hours at five time points over 30 days.
Number of subjects: 50
Study 31320356 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (20 participants) with 15-hour EEG/ERP recording for baseline comparison.
Number of subjects: 50
Study 31320358 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening using dried blood spot (DBS) sampling and collection of sociodemographic, economic and behavioural data.
Number of subjects: 0
Study 31320358 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening and first clinic visit.
Number of subjects: 0
Study 31320358 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparisons of health and economic outcomes between households affected by HBV versus non-affected households.
Number of subjects: 0
Study 31320358 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation of scaling-up HBV care.
Number of subjects: 0
Study 31320445 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression to normal glucose regulation (NGR)
Number of subjects: 0
Study 31320445 — intervention group
Group type: EXPERIMENTAL
Intervention: Average A1C during follow-up
Number of subjects: 0
Study 31320894 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Shock Wave Therapy
Number of subjects: 0
Study 31321070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted resistance training intervention
Number of subjects: 0
Study 31321070 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31321442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4036
Study 31321442 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 4036
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi monotherapy (existing use)
Number of subjects: 700
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: csDMARD monotherapy (existing use)
Number of subjects: 700
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (existing use)
Number of subjects: 700
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi monotherapy (initiated use)
Number of subjects: 700
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: csDMARD monotherapy (initiated use)
Number of subjects: 700
Study 31321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (initiated use)
Number of subjects: 700
Study 31321631 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg + single-dose rosuvastatin 10 mg
Number of subjects: 0
Study 31321631 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg + single-dose atorvastatin 10 mg
Number of subjects: 0
Study 31321875 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + RPV
Number of subjects: 288
Study 31321875 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + darunavir/COBI
Number of subjects: 288
Study 31321875 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG
Number of subjects: 288
Study 31321875 — intervention group
Group type: EXPERIMENTAL
Intervention: COBI
Number of subjects: 288